Neukio Biotherapeutics is a developer of allogenic immune cell therapies for treatment of cancer.
Neukio Biotherapeutics is an immune cell drug developer, focusing on the research and development and industrialization of immune cell drugs, developing iPSC-CAR-NK general-purpose spot immune cell products, and is committed to providing effective therapeutic drugs for cancer patients around the world.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 2, 2022 | Series A | $50M | 3 | — | — | Detail |
Jul 29, 2021 | Angel | $40M | 1 | Lilly Asia Ventures | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Yahui Precision Medicine Fund | — | Series A |
Kuanyu Private Equity | — | Series A |
Lilly Asia Ventures | — | Series A |